Cyclobenzaprine (Flexeril) Dosing
For most adults, start cyclobenzaprine at 5 mg three times daily, which provides equivalent efficacy to 10 mg three times daily but with significantly less sedation. 1, 2
Standard Adult Dosing
Immediate-Release Formulation:
- Starting dose: 5 mg three times daily (TID) 2
- Alternative dose: 10 mg TID if 5 mg proves insufficient 1
- Maximum dose: 10 mg TID 1
- Duration: 2-3 weeks maximum 1
The 5 mg TID regimen demonstrates comparable efficacy to 10 mg TID for acute musculoskeletal spasm while producing substantially lower rates of somnolence and anticholinergic effects 2. The 2.5 mg TID dose is not significantly more effective than placebo and should not be used 2.
Extended-Release Formulation:
- Starting dose: 15 mg once daily 1
- Maximum dose: 30 mg once daily (or two 15 mg capsules once daily) 1
- Timing: Same time each day 1
- Administration: Swallow intact OR sprinkle contents on applesauce and swallow immediately without chewing 1
Elderly Patients (≥65 Years)
Reduce the dose or dosing frequency in all elderly patients due to significantly altered pharmacokinetics. 1, 3
- Plasma AUC increases by 40% in elderly patients 1
- Half-life extends to 50 hours (versus 32 hours in younger adults) 1, 3
- Steady-state concentrations are twice as high as in younger patients 3
Recommended approach for elderly:
- Start with 5 mg once or twice daily (rather than TID)
- Titrate cautiously based on response and tolerability
- Consider extended-release 15 mg once daily as alternative 4
- Monitor closely for anticholinergic effects, sedation, and falls risk
The 2019 AGS Beers Criteria specifically lists cyclobenzaprine among muscle relaxants to avoid in older adults due to increased risk of sedation, anticholinergic effects, and fractures 5. When use is deemed necessary, employ the lowest effective dose for the shortest duration.
Hepatic Impairment
Avoid cyclobenzaprine in moderate to severe hepatic impairment; if mild hepatic impairment exists, reduce dose substantially. 1, 3
- Mild hepatic impairment: AUC and Cmax approximately double compared to healthy controls 1
- Steady-state concentrations: Up to twofold higher 3
- Severe hepatic impairment: Pharmacokinetics unknown; avoid use 1
Dosing recommendation for mild hepatic impairment:
- Start with 5 mg once daily
- Increase cautiously only if necessary
- Extended monitoring for adverse effects required
Renal Impairment
No specific dose adjustment is required for renal impairment as cyclobenzaprine is primarily metabolized hepatically and excreted as glucuronides 1. However, exercise caution in severe renal disease due to potential accumulation of metabolites.
Duration of Therapy
Limit treatment to 2-3 weeks maximum. 1
Cyclobenzaprine is indicated only for acute musculoskeletal conditions. Evidence does not support use beyond 2-3 weeks, and prolonged use increases risks of tolerance, dependence, and adverse effects 1. The drug's efficacy for chronic conditions is not established.
Critical Prescribing Considerations
Anticholinergic burden: Cyclobenzaprine has potent anticholinergic effects similar to tricyclic antidepressants 1. Avoid in patients with:
- Urinary retention
- Angle-closure glaucoma
- Cognitive impairment
- Concurrent anticholinergic medications
Sedation profile: The most common adverse effect is dose-dependent somnolence 2. Warn patients about:
- Impaired driving and operating machinery
- Additive effects with alcohol and CNS depressants
- Risk of falls, particularly in elderly
Drug interactions: Cyclobenzaprine is metabolized by CYP3A4, CYP1A2, and CYP2D6 1. Monitor for interactions with:
- MAO inhibitors (contraindicated within 14 days)
- Other serotonergic agents (serotonin syndrome risk)
- CYP3A4 inhibitors (increased cyclobenzaprine levels)
Clinical efficacy context: Recent high-quality evidence demonstrates that adding cyclobenzaprine to naproxen provides no additional benefit over naproxen alone for acute low back pain 6. Consider whether monotherapy with an NSAID or acetaminophen is sufficient before adding cyclobenzaprine.